CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Fluidigm Corporation |
Dr. Marc A Unger |
Tools and Technologies II |
Development and Application of Versatile, Automated, Microfluidic Cell Culture System |
$1,939,236 |
| University of California, Los Angeles |
Dr. Martin Gabriel Martin |
Tools and Technologies II |
Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders |
$1,783,250 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$697,507 |
| University of California, San Francisco |
Dr. Arturo Alvarez-Buylla |
Early Translational II |
Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy |
$1,564,016 |
| University of California, Davis |
Dr. Mark Zern |
Early Translational II |
Liver Cell Transplantation |
$4,212,621 |
| Stanford University |
Dr. Michele Calos |
Early Translational II |
Stem Cell Therapy for Duchenne Muscular Dystrophy |
$2,267,261 |
| University of California, Irvine |
Dr. Brian J. Cummings |
Early Translational II |
Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury |
$1,517,767 |
| University of California, Los Angeles |
Dr. Sophie X Deng |
Early Translational II |
Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$1,524,947 |
| Cedars-Sinai Medical Center |
Dr. Dan Gazit |
Early Translational II |
Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures |
$1,927,698 |
| University of California, Los Angeles |
Leif Havton |
Early Translational II |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$75,628 |
| University of California, Irvine |
Leif A Havton |
Early Translational II |
Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$1,527,011 |
| City of Hope, Beckman Research Institute |
Dr. Yanhong Shi Ph.D. |
Early Translational II |
Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell |
$1,835,983 |
| City of Hope, Beckman Research Institute |
Dr. David Louis DiGiusto |
Early Translational II |
Development of RNA-based approaches to stem cell gene therapy for HIV |
$3,097,160 |
| University of California, Davis |
Dr. Roslyn Rivkah Isseroff |
Early Translational II |
Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds |
$4,629,747 |
| University of California, Los Angeles |
Dr. Noriyuki Kasahara |
Early Translational II |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,340,625 |
| Salk Institute for Biological Studies |
Dr. Fred H Gage |
Early Translational II |
Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model |
$2,472,839 |
| University of California, Irvine |
Dr. Henry John Klassen |
Early Translational II |
Human retinal progenitor cells as candidate therapy for retinitis pigmentosa |
$1,803,768 |
| Children’s Hospital of Los Angeles |
Dr. Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$850,769 |
| University of California, San Francisco |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$2,756,536 |
| Buck Institute for Age Research |
Dr. Xianmin Zeng |
Early Translational II |
Banking transplant ready dopaminergic neurons using a scalable process |
$4,983,013 |
| iPierian, Inc. |
Dr. John Dimos |
Early Translational II |
New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells |
$2,410,000 |
| University of California, Los Angeles |
Prof. Bruno Peault |
Early Translational II |
Harnessing native fat-residing stem cells for bone regeneration |
$5,359,076 |
| Scripps Research Institute |
Peter G. Schultz |
Early Translational II |
Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,047,249 |
| University of California, San Diego |
Professor Alysson R Muotri |
Early Translational II |
Developing a drug-screening system for Autism Spectrum Disorders using human neurons |
$1,376,198 |
| University of California, Irvine |
Dr. Leslie M Thompson |
Early Translational II |
A hESc-based Development Candidate for Huntington’s Disease |
$3,955,038 |
| University of California, San Diego |
Catriona Jamieson |
Early Translational II |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,103,041 |
| Gladstone Institutes, J. David |
Dr. Todd C. McDevitt |
Research Leadership |
Engineering microscale tissue constructs from human pluripotent stem cells |
$5,849,100 |
| University of California, Los Angeles |
Dr. John P Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
| University of California, Berkeley |
Dr. Xavier Darzacq |
Research Leadership |
Single Molecule Biophysics and Biology of Cellular Identity |
$4,175,924 |
| University of California, San Francisco |
Redacted |
Research Leadership |
Recapitulating development of the musculoskeletal axis in vitro with pluripotent cells |
$0 |
| University of California, San Diego |
Dr. Eric T. Ahrens |
Research Leadership |
Molecular Imaging for Stem Cell Science and Clinical Application |
$5,680,474 |
| University of California, Santa Cruz |
Professor Richard Gregory |
Research Leadership |
MicroRNA Regulation in Stem Cells, Development, and Disease |
$0 |
| Stanford University |
Professor Hiromitsu Nakauchi |
Research Leadership |
Generation of functional cells and organs from iPSCs |
$5,426,135 |
| Gladstone Institutes, J. David |
Dr. Kevin Kit Parker PhD |
Research Leadership |
Engineering Cardiac Tissue for Regeneration and Drug Development |
$0 |
| Cedars-Sinai Medical Center |
Dr. Barry R Stripp |
Research Leadership |
Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
| Parkinson’s Institute |
Dennis Steindler |
Research Leadership |
Stem Cell Pathologies in Parkinson’s disease as a key to Regenerative Strategies |
$0 |
| University of Southern California |
Dr. Andrew McMahon |
Research Leadership |
Repair and regeneration of the nephron |
$5,672,206 |
| University of California, Berkeley |
Dr. Zhigang He |
Research Leadership |
Developing a regeneration-based functional restoration treatment for spinal cord injury |
$0 |
| University of California, Santa Barbara |
Professor Peter J Coffey |
Research Leadership |
Development of Cellular Therapies for Retinal Disease |
$4,690,963 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Robert J Wechsler-Reya |
Research Leadership |
The role of neural stem cells in cerebellar development, regeneration and tumorigenesis |
$5,226,049 |
| Mohammad Pashmforoush |
Dr. Mohammad Pashmforoush |
New Faculty I |
Medical School Loan Repayment Program |
$27,949 |
| Salk Institute for Biological Studies |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$2,134,100 |
| University of California, Los Angeles |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$382,773 |
| University of California, Los Angeles |
Dr. Siavash Kurdistani |
New Faculty I |
Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
| University of California, Santa Cruz |
Dr. Camilla Forsberg |
New Faculty I |
Mechanisms of Stem Cell Fate Decisions |
$2,201,759 |
| University of Southern California |
Dr. Mohammad Pashmforoush |
New Faculty I |
Transcriptional Regulation of Cardiac Pacemaker Cell Progenitors |
$2,816,578 |
| University of California, Berkeley |
Dr. Irina M. Conboy |
New Faculty I |
Identification of hESC-mediated molecular mechanism that positively regulates the regenerative capacity of post-natal tissues |
$2,246,020 |
| University of California, Santa Cruz |
Dr. Bin Chen |
New Faculty I |
Molecular mechanisms of neural stem cell differentiation in the developing brain |
$2,147,592 |
| University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
New Faculty I |
In vitro reprogramming of mouse and human somatic cells to an embryonic state |
$2,229,427 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Douglas Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$621,639 |
